Protalix BioTherapeutics, Inc.

NYSEAM:PLX 株式レポート

時価総額：US$174.0m

Protalix BioTherapeutics マネジメント

マネジメント 基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Dror Bashan

最高経営責任者

US$1.2m

報酬総額

CEO給与比率34.44%
CEO在任期間7yrs
CEOの所有権3.1%
経営陣の平均在職期間5.4yrs
取締役会の平均在任期間6.4yrs

経営陣の近況

Recent updates

ナラティブの更新 • Jun 05

PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside

Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.
ナラティブの更新 • May 11

PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside

Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).
ナラティブの更新 • Apr 26

PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside

Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.
ナラティブの更新 • Apr 09

PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside

Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).
ナラティブの更新 • Mar 26

PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside

Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).
ナラティブの更新 • Mar 09

PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook

Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).
ナラティブの更新 • Feb 23

PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook

Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).
ナラティブの更新 • Feb 08

PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside

Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).
ナラティブの更新 • Jan 24

PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential

Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).
ナラティブの更新 • Jan 10

PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential

Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.
ナラティブの更新 • Dec 16

PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential

Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.
ナラティブの更新 • Dec 02

PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential

Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.
ナラティブの更新 • Nov 18

PLX: European Review Process Will Drive Next Phase Of Momentum

Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
User avatar
新しいナラティブ • May 19

Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth

As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
User avatar
新しいナラティブ • Apr 29

PRX-115 Trials And Elfabrio Launch Will Open Future Markets

Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.
分析記事 • Feb 22

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...
分析記事 • Jan 14

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
分析記事 • Dec 10

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...

CEO報酬分析

Protalix BioTherapeutics の収益と比較して、Dror Bashan の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

US$15m

Dec 31 2025US$1mUS$402k

-US$7m

Sep 30 2025n/an/a

US$5m

Jun 30 2025n/an/a

US$6m

Mar 31 2025n/an/a

US$4m

Dec 31 2024US$2mUS$374k

US$3m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

US$7m

Dec 31 2023US$3mUS$357k

US$8m

Sep 30 2023n/an/a

US$11m

Jun 30 2023n/an/a

US$9m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$1mUS$360k

-US$15m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$24m

Dec 31 2021US$1mUS$374k

-US$28m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$1mUS$352k

-US$7m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$566kUS$175k

-US$18m

報酬と市場: Drorの 総報酬 ($USD 1.17M ) は、 US市場 ($USD 1.63M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Drorの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Dror Bashan (59 yo)

7yrs
在職期間
US$1,166,934
報酬

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Dror Bashan
President7yrsUS$1.17m3.14%
$ 5.5m
Gilad Mamlok
Senior VPless than a yearUS$539.14k0.0045%
$ 7.8k
Yaron Naos
SVP & COO8.1yrsUS$575.77k0.29%
$ 501.8k
Yael Fellous
Vice President of Human Resources3.8yrsデータなしデータなし
5.4yrs
平均在職期間
59yo
平均年齢

経験豊富な経営陣: PLXの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称ポジション在職期間報酬所有権
Dror Bashan
President7yrsUS$1.17m3.14%
$ 5.5m
Amos Shalev
Independent Director17.9yrsUS$71.71k0.0093%
$ 16.2k
Aharon Schwartz
Independent Director11.6yrsUS$71.71k0.39%
$ 670.7k
Gwen A. Melincoff
Independent Director6.4yrsUS$71.71k0.0093%
$ 16.2k
Charles Arntzen
Member of Scientific Advisory Board10yrsデータなしデータなし
Alexander Levitzki
Member of Scientific Advisory Boardno dataデータなしデータなし
Shmuel Ben-Zvi
Independent Director4yrsUS$71.34k0.0093%
$ 16.2k
Roger Kornberg
Chairman of Scientific Advisory Boardno dataUS$55.00kデータなし
Eliot Forster
Independent Chairman2.8yrsUS$99.58k0.0093%
$ 16.2k
Pol Boudes
Independent Director6.4yrsUS$71.71k0.0094%
$ 16.3k
Christian Elze
Director1yrUS$20.08k0.0093%
$ 16.2k
6.4yrs
平均在職期間
73yo
平均年齢

経験豊富なボード: PLXの 取締役会 は 経験豊富 であると考えられます ( 6.4年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/23 22:11
終値2026/06/23 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Protalix BioTherapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8

アナリスト機関
Ritu BaralCanaccord Genuity
Raghuram SelvarajuH.C. Wainwright & Co.
Peter WelfordJefferies LLC